Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Aug 05, 2024 12:50pm
59 Views
Post# 36164750

RE:RE:RE:RE:RE:RE:RE:RE:Stock Market Shifts into Small Caps

RE:RE:RE:RE:RE:RE:RE:RE:Stock Market Shifts into Small Caps " ....with the issues of patent expiration facing Big Pharma, their focus is M&A of smaller biotech companies in order to sustain growth and to help outperform the general market ..."

and the rotation into small caps is beginning 

Two reasons this is happening now


1) The fundamentals. We are moving into a “Goldilocks” scenario for the Federal Reserve. Inflation is coming down, and growth is moderating but not stalling. The inflation data continues to give us more confidence that inflation is no longer threatening. Last week’s CPI report showed the first month-over-month decrease since 2020, and Bank of America’s Institutional Fund Manager survey showed that higher inflation is no longer investors’ number-one tail risk.

This backdrop of decent growth with fading inflation pressures and room to cut rates is compelling for risk assets. 

2) The technicals. Given the smaller size and relatively less liquidity of the small-cap market, technicals also play a bigger role. Hedge funds came into the month with a near-record short position in small caps. When positioning is that stretched, it only takes a small spark to ignite a powerful rotation.

 

<< Previous
Bullboard Posts
Next >>